 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...4546474849505152535455...123124» |
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Metastases: Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT (clinicaltrials.gov) - Oct 24, 2022
P=N/A, N=100, Recruiting, Sponsor: Sun Yat-sen University
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
SIMILAR EFFICACY AND SAFETY BETWEEN LENVATINIB VERSUS ATEZOLIZUMAB PLUS BEVACIZUMAB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2161;
The efficacy and safety of lenvatinib are similar to atezolizumab plus bevacizumab as a primary systemic therapy for unresectable HCC.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
OUTCOMES OF SYSTEMIC THERAPY FOR HEPATOCELLULAR CARCINOMA WITH MAJOR PORTAL VEIN THROMBOSIS () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2159;
Lenvatinib-based treatment could provide better ORR, PFS, and OS for HCC patients with Vp3/Vp4 portal vein invasion. However, the risk of hepatic encephalopathy by lenvatinib treatment should be aware.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
THE LIVER FRAILTY INDEX IS AN INDEPENDENT PREDICTOR OF MORTALITY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA UNDERGOING SYSTEMIC THERAPY – A MULTICENTRE PROSPECTIVE OBSERVATIONAL STUDY () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2153;
With new cut-offs specific for advanced HCC, it becomes an independent predictor of mortality. This may help guide patient selection.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
EFFICACY OF LENVATINIB IN INTERMEDIATE STAGE UNRESECTABLE HEPATOCELLULAR CARCINOMA () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2152;
The efficacy of lenvatinib in the treatment of intermediate stage u-HCC was favorable. The combination of lenvatinib and TACE may improve further prognosis even in patients who are refractory or unsuitable for TACE.
- MUSCLE ATTENUATION IS ASSOCIATED WITH SURVIVAL RATE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA UNDERGOING SYSTEMIC TREATMENT () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2147;
Patients received treatment with either sorafenib (n=60), lenvatinib (n=14), pembrolizumab (n=1), atezolizumab and bevacicumab (n=19), tremelimumab and durvalumab (n=3) or tislelizumab (n=1) for a mean duration of 7.5 (range, 0-61) months. MA is an efficient tool for identifying patients with poor survival before systemic HCC treatment that should be validated in larger patient cohorts.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS ARE ASSOCIATED WITH FAVORABLE OUTCOME IN PATIENTS WITH ADVANCED HCC TREATED WITH LENVATINIB () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2138;
In addition, the higher MAIT frequency (>1.5%) in peripheral blood was associated with favorable outcome in advanced HCC patients treated with lenvatinib therapy. Further study is needed to evaluate the role of memory T cell subsets in MAIT cells and the dynamic change of MAIT cell phenotypes during lenvatinib therapy.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
THE IMPORTANCE OF BODY COMPOSITION MEASUREMENTS DURING LENVATINIB TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA. () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2124;
Further study is needed to evaluate the role of memory T cell subsets in MAIT cells and the dynamic change of MAIT cell phenotypes during lenvatinib therapy. Body composition assessment by BIA before and after lenvatinib treatment is useful in predicting prognosis in lenvatinib-treated patients with HCC.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
EMERGING REAL-WORLD TREATMENT PATTERNS FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (uHCC) PATIENTS FOLLOWING APPROVAL OF ATEZOLIZUMAB PLUS BEVACIZUMAB (A+B) IN THE UNITED STATES (US) () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2118;
P3
While baseline characteristics were similar among A+B, LEN, and SOR patients, NIVO patients had worse ECOG PS and liver dysfunction. Real-world treatment patterns suggest use of A+B in patients with worse ECOG PS and liver dysfunction than those included in IMbrave150.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
USEFULNESS OF LIQUID BIOPSY BASED ON A METHYLATED SEPT9 ASSAY IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH MOLECULAR TARGETED AGENTS () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2085;
The m- SEPT9 is a beneficial prognosis prediction marker in HCC patients treated with MTA. We suggest that the MTA score contributes to the selection for appropriate sequential treatment.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
THE BENEFICIAL IMPACT OF METABOLIC DYSFUNCTION ASSOCIATED WITH FATTY LIVER DISEASE IN PATIENTS WITH NON-VIRAL HEPATOCELLULAR CARCINOMA TREATED WITH LENVATINIB: AN INTERNATIONAL STUDY () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2070;
The OS of patients with HCC was significantly higher in the MAFLD group than in the non-MAFLD group. Moreover, the higher OS of the MAFLD group was observed in patients with non-virus HCC, but not in patients with virus HCC.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
INCIDENCE AND RISK FACTORS OF ESOPHAGOGASTRIC VARICES BLEEDING IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH LENVATINIB () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2052;
Moreover, the higher OS of the MAFLD group was observed in patients with non-virus HCC, but not in patients with virus HCC. In HCC patients to be treated with LEN, a UGE screening could be useful to identify the few patients at moderate to high risk of EGV bleeding, such as those with decompensated cirrhosis, nPVT and low platelets’ count.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
COMPARISON OF ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB IN TERMS OF EFFICACY AND SAFETY AS PRIMARY SYSTEMIC CHEMOTHERAPY FOR HEPATOCELLULAR CARCINOMA () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2046;
In HCC patients to be treated with LEN, a UGE screening could be useful to identify the few patients at moderate to high risk of EGV bleeding, such as those with decompensated cirrhosis, nPVT and low platelets’ count. Atezolizumab plus bevacizumab showed prolonged PFS, maintained hepatic reserve, and had lower rates of severe AEs compared with that on using lenvatinib as primary systemic chemotherapy for HCC.
- PARADIGM SHIFT OF SYSTEMIC THERAPIES FOR HEPATOCELLULAR CARCINOMA (HCC) – A TERRITORY-WIDE STUDY FROM 2012-2021 () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2045;
sorafenib, with a steady increase in the utilization of immune checkpoint inhibitors i.e . pembrolizumab.
- Transarterial radioembolization (TARE) is a safe and effective treatment modality for patients with advanced hepatocellular carcinoma. () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2044;
TARE is a safe and effective treatment modality for patients with advanced hepatocellular carcinoma, associated with overall survival of 14 months. TARE can also be the bridge to definitive therapies, including liver transplantation.
- THE CURRENT MTAs FOR HEPATOCELLULAR CARCINOMA HAVE DIFFERENT EFFECTS ON THE TUMOR IMMUNE MICROENVIRONMENT -A COMPREHENSIVE IMMUNOHISTOCHEMISTRICAL ANALYSIS- () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2035;
In the orthotopic xenograft mice model for HCC, LEN and AZD4547, which commonly inhibit FGFR signaling, altered the TIME from cold to hot. The findings obtained from this study support the therapeutic concept in the era of multi-MTAs including ICIs.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
SPONTANEOUSLY RUPTURED HEPATOCELLULAR CARCINOMA ON NON-CIRRHOTIC LIVER: TREATMENT AND PROGNOSIS. () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2034;
Initial hemostasis was achieved in all patients by TAE/TACE or surgery. Subsequent treatment was individualized, according to the number and size of nodules.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
HIGHER NUMBER OF TUMOR-INFILTRATING T CELLS/ PD-L1+ CELLS AS A FAVORABLE PREDICTOR OF LENVATINIB RESPONSE () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2024;
Background : Sorafenib and lenvatinib are multikinase inhibitors approved for the unresectable hepatocellular carcinoma (HCC). Tumor immunogenicity, as indicated by the frequency of infiltrating T cells and PD-L1 + cells in TME, might be an indicator for objective response to multikinase inhibitor treatment.
- Tecentriq (atezolizumab) / Roche
ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): REAL-WORLD EXPERIENCE FROM A US COMMUNITY ONCOLOGY NETWORK () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2022;
While more patients had poor prognostic factors for HCC in the real-world setting compared to the IMbrave150 cohort, the median real-world TTNT was found to be in line with the median progression-free survival in IMbrave150, providing early evidence supporting the real-world performance of A+B. Further research with longer follow-up assessing real-world effectiveness and safety of A+B is needed.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
BLOCKADE OF ANGIOTENSIN-II AUGMENTS THE RESPONSIVENESS OF HUMAN LIVER CANCER CELLS TO LENVATINIB () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2019;
This combination regimen may provide advantageous outcomes to patients with intolerance to a common dose of lenvatinib due to adverse effects including hypertension. Given that AT-II blockers are clinically available without severe toxicities, they may eventually emerge as viable modulators of molecular targeted agents for patients with advanced HCC.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
ABSOLUTE BENEFIT OF LENVATINIB PLUS ANTI-PD-1 FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA FROM A REAL WORLD STUDY () - Oct 23, 2022 - Abstract #AASLD2022AASLD_2018;
Lenvatinib plus anti-PD-1 showed a favorable efficacy and controllable safety for u-HCC patients in real-world practice. The absolute improvement of the 12-month survival rate with combination therapy compared with monotherapy was more substantial in patients with MVI or EHS and CPB.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
INTESTINAL PERMEABILITY PREDICTS SERIOUS ADVERSE EVENTS IN ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH LENVATINIB () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1992;
Baseline serum zonulin levels can help identify potential SAEs to assist safe management. However, a larger study is required for the validation of surrogate biomarkers for estimating the occurrence and severity of AEs in systemic chemotherapy for HCC, such as with lenvatinib.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
TARGETING CHRONIC VEGF-C SIGNALING MITIGATES DISEASE PROGRESSION IN NON-ALCOHOLIC STEATOHEPATITIS () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1210;
However, a larger study is required for the validation of surrogate biomarkers for estimating the occurrence and severity of AEs in systemic chemotherapy for HCC, such as with lenvatinib. Taken together, these findings indicate that chronic VEGF-C production in NASH plays a role in propagating liver fibrosis and steatosis, and that blockade of the downstream receptors for VEGF-C, VEGFR2 and VEGFR3, may be a promising therapeutic strategy to mitigate disease severity.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
NOVEL APPROACHES TO IMPROVE IMMUNOTHERAPY FOR NASH-INDUCED HCC () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1206;
Until recently, multi-kinase inhibitor like sorafenib and Lenvatinib have been standard of care (SOC) for patients with advanced-stage HCC. Combining metabolic-regulating reagents with ICI could become a novel therapeutic strategy for NASH-related HCC.
- Keytruda (pembrolizumab) / Merck (MSD), Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
SYSTEMIC CHEMOTHERAPY FOR HEPATOCELLULAR CARCINOMA TREATMENT AND SUBSEQUENT POST-TRANSPLANT COMPLICATIONS () - Oct 23, 2022 - Abstract #AASLD2022AASLD_938;
Locoregional therapies also have a significantly higher rate of HAS. This study highlights a further area of investigation for HCC patients undergoing transplantation and possible complications.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
LENVATINIB PREVENTS LIVER FIBROSIS BY INHIBITING HEPATIC STELLATE CELL ACTIVATION AND SINUSOIDAL CAPILLARIZATION IN MURINE EXPERIMENTAL LIVER FIBROSIS () - Oct 23, 2022 - Abstract #AASLD2022AASLD_831;
It is important to emphasize that these actions of lenvatinib were achieved using a pharmacological dose without toxic hepatocytes damage. Although lenvatinib has been approved for the treatment of HCC, our findings indicate that this drug could be used as a novel therapeutic option for liver fibrosis development.
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal: Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. (Pubmed Central) - Oct 23, 2022
ATEZO/BEVA showed superiority to LEN in terms of prognosis and conversion rate as first-line therapy. Moreover, ATEZO/BEVA had a lower rate of severe adverse events, except for bleeding, than LEN.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-Differentiated Neuroendocrine Tumors (JW Marriott Washington, D.C.) - Oct 23, 2022 - Abstract #NANETS2022NANETS_68;
Two patients discontinued treatment prior to radiographic assessment. CONCLUSIONS The combination of pembrolizumab and lenvatinib did not show sufficient response in patients with NETs to warrant continued enrollment on trial.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal, Tumor microenvironment: The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. (Pubmed Central) - Oct 22, 2022
On the other hand, gene expression levels of fibroblast growth factor receptors were upregulated in VETC+ HCC, suggesting that VETC+ HCC might benefit from lenvatinib treatment. Our results demonstrate that VETC+ HCC was associated with the suppression of tumor immune responses at the molecular level.
- Lartruvo (olaratumab) / Eli Lilly, Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Thermal ablation followed by intratumoral injection of a novel immune stimulant IP-001 in patients with advanced solid tumors: Phase IB part of study SAKK 66/17 (Foyer ABC) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_347;
P1/2
Conclusions TA followed by IP-001 at a dose of 4 mL is well tolerated in pts with advanced solid tumors who have failed standard treatment. The combined use of thermal tumor ablation and IP-001® at a dose of 4 ml can safely be administered in patients with advanced solid malignancies with the potential to stimulate an abscopal effect via immune stimulation.
- Baizean (tislelizumab) / BeiGene, Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of tislelizumab (TIS) plus lenvatinib (LEN) as first-line treatment in patients (pts) with unresectable hepatocellular carcinoma (uHCC): a single-arm, multicenter, phase II trial (Foyer ABC) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_318;
P2
Table: 165P Confirmed tumor response per RECIST v1.1 (efficacy evaluable analysis set*, n=62) IRC Investigator review Objective Response Rate, % (95% CI) 38.7 (26.6, 51.9) 41.9 (29.5, 55.2) Best Overall Response, n (%) Complete Response 0 (0.0) 1 (1.6) Partial Response 24 (38.7) 25 (40.3) Stable Disease 32 (51.6) 27 (43.5) Progressive Disease 5 (8.1) 8 (12.9) Not Assessable 1 (1.6) 1 (1.6) Disease Control Rate, % (95% CI) 90.3 (80.1, 96.4) 85.5 (74.2, 93.1) ∗Include pts with measurable disease at baseline per RECIST v1.1 who had ≥1 dose of TIS or LEN, and had ≥1 post-baseline tumor assessment (included 1 patient who died with confirmed clinical disease progression before the first radiological assessment). Conclusions TIS plus LEN showed promising antitumor activity with acceptable safety profile as first-line treatment for uHCC.
- Baizean (tislelizumab) / BeiGene, Novartis
Efficacy and Safety of Tislelizumab Combined with Targeted Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Real-world Study (Foyer ABC) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_294;
P
Conclusions In the real-world setting, tislelizumab plus targeted therapy shows favorable efficacy with reasonable tolerability as 1L treatment options for patients with unresectable HCC. The combination may also provide an opportunity for curative resection.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab. (Foyer mezzanine) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_261;
There was no difference in objective response rate (ORR) between the two groups (high 26.1% vs. low 19.8%, p = 0.09), while disease control rate (DCR) was significantly higher in the PNI-high group (76.8% vs. 66.4%, p = 0.01). Conclusions PNI is an independent prognostic factor for OS and PFS in HCC patients on first-line treatment with atezolizumab plus bevacizumab.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
A Multicenter Retrospective Cohort Study Comparing the Efficacy and Safety of Lenvatinib in Combination with PD-1 Inhibitor with or without Transarterial Chemoembolization in Patients with unresectable Hepatocellular Carcinoma (Foyer mezzanine) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_255;
In terms of effectiveness and survival time, the LPT therapy model outperforms the LP mode. The potential of the LPT should be evaluated in prospective cohort investigations.
- Baizean (tislelizumab) / BeiGene, Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Hepatic arterial infusion chemotherapy(HAIC) + Lenvatinib(len) and tislelizumab(tis) ±transhepatic arterial embolization(TAE) for unresectable hepatocellular carcinoma(uHCC) with portal vein tumor thrombus(PVTT) and high tumor-burden: A multicenter retrospective study (Foyer mezzanine) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_241;
Grade 3/4 treatment-related AEs were more frequent in the THLP group than in the HLP group including abdominal pain (34% vs 18%), Nausea (36% vs 22%), and elevated transaminases (10% vs 2%), but there AEs were completely controllable and no treatment-related death happened. Conclusions Additional TAE to triple combination therapy of HAIC, len and tis might improve prognosis compared with triple combination therapy and had accepted toxic effects.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Clinical outcomes with atezolizumab plus bevacizumab (AB) or lenvatinib (L) in hepatocellular carcinoma (HCC). (Foyer mezzanine) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_231;
P who achieve CR with AB can achieve OS so far never recorded in HCC patients. This study didn't highlight any factors that could identify HCC P subgroups capable of obtaining CR.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Atezolizumab plus bevacizumab versus Lenvatinib for unresectable hepatocellular carcinoma: a large real life worldwide population (Foyer mezzanine) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_218;
Conclusions Our study did not identify any meaningful difference in overall survival between atezolizumab plus bevacizumab and lenvatinib. Although some hints are provided suggesting that patients with NASH/NAFLD might benefit more from lenvatinib therapy and patients with viral etiology more from atezolizumab plus bevacizumab.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Heterogeneity: Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer. (Pubmed Central) - Oct 21, 2022
Acquired sorafenib resistance in organoids promotes HCC aggressiveness via facilitating stemness, retro-differentiation and EMT. Phosphorylated S6 kinase may be predictive for drug resistance in HCC.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial suspension, Metastases: Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Oct 21, 2022
P2, N=22, Suspended, Sponsor: Emory University
Phosphorylated S6 kinase may be predictive for drug resistance in HCC. Recruiting --> Suspended
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: What do you think about this choice of lenvantinib and pembrolizumab for this patient? @montypal @OncoBellmunt @EvanHallMD @DrChoueiri @BraunMDPhD @PBarataMD @Andres_Matoso @brian_rini (Twitter) - Oct 20, 2022
- Gilotrif (afatinib) / Boehringer Ingelheim, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Patient vignettes reflecting the impact of The Australian Rare Cancer Portal on patients with rare cancer (Great Hall 3&4) - Oct 20, 2022 - Abstract #COSA2022COSA_349;
Conclusion The ARC Portal offers patients access to excellent rare cancer care. Formal assessment of relevant endpoints is underway.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
LEAP-009: Phase 2 study of Lenvatinib with or without Pembrolizumab vs chemotherapy for the treatment of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) upon progression after platinum and immunotherapy (PD-1/PD-L1 Inhibition) (Great Hall 3&4) - Oct 20, 2022 - Abstract #COSA2022COSA_186;
P2
Results of LEAP-009 will provide clarification on the efficacy and safety of lenvatinib with or without pembrolizumab vs chemotherapy for patients with R/M HNSCC upon progression after platinum and immunotherapy. Clinical trial registration: NCT04428151
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study (Great Hall 3&4) - Oct 20, 2022 - Abstract #COSA2022COSA_181;
P3
- Reused with permission ClinicalTrials.gov number: NCT02811861 Funding source: This study was sponsored by Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Medical writing support was provided by Irene Minkina, PhD, of Oxford PharmaGenesis Inc., Newtown, PA, USA, with funding by Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving Lenvatinib + Pembrolizumab (CLEAR Study) (Great Hall 3&4) - Oct 20, 2022 - Abstract #COSA2022COSA_180;
P3
Clinical trial information: NCT02811861 Funding: This study was sponsored by Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Medical writing support was provided by Oxford PharmaGenesis Inc., Newtown, PA, USA, with funding by Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
- ||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
P3 data, Journal: Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. (Pubmed Central) - Oct 20, 2022
Medical writing support was provided by Oxford PharmaGenesis Inc., Newtown, PA, USA, with funding by Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. At extended follow-up, cabozantinib maintained superior efficacy over a placebo in patients with previously treated RAIR-DTC with no new safety signals.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
VALIDATION OF A PROGNOSTIC NOMOGRAM TO PREDICT PFS IN METASTATIC ADENOID CYSTIC CARCINOMA PATIENTS TREATED WITH LENVATINIB () - Oct 19, 2022 - Abstract #AIOM2022AIOM_89;
This post-hoc analysis data showed a trend towards better survival for LR vs. HR pts. The worse PFS of HR pts (50%) vs.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
SEQUENTIAL MOLECULAR PROFILING OF ADVANCED THYROID CANCERS FOR PRECISION ONCOLOGY: FLOWCHART FROM AN ITALIAN REFERRAL CENTER (Titian Room 2) - Oct 19, 2022 - Abstract #AIOM2022AIOM_85;
Patients with good PS and no access to standard treatments should have the opportunity of being offered molecular analysis to expand their therapeutic options. The choice of the most appropriate tests and sequence is crucial to assure cost-effectiveness and rapid results.
- IO-IO VS IO-TKI COMBINATION AS FIRST LINE TREATMENT OF MRCC PATIENTS: A MONOCENTRIC EXPERIENCE () - Oct 19, 2022 - Abstract #AIOM2022AIOM_74;
Our study represents a real-world evidence of first line therapy combinations and we hope that the ongoing analysis of a custom NGS panel could generate data to inform clinicians and helping therapeutic decision making process. Finding predictive biomarkers for choos- ing the most suitable treatment for every pts and overcom- ing therapy resistance remains an unmet need in mRCC.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: A Case of Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib. (Pubmed Central) - Oct 19, 2022
We also observed damage to the renal tubules, where PDGFR is located. To our knowledge, this is the first report of lenvatinib-induced damage to the renal tubules.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Tyrosine kinase inhibitor treatment and long-term follow-up for metastatic malignant struma ovarii. (Pubmed Central) - Oct 19, 2022
She subsequently received treatment with the tyrosine kinase inhibitors (TKIs), sorafenib and then lenvatinib, as treatments for advanced disease, thereby achieving long-term disease stability. This case report, which adds to the limited data available on MMSO treatment, suggests that patients treated with a combination of radioactive iodine, radiation therapy, and TKIs can result in good responses and long-term overall survival.